Breakdown | ||||
Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
130.13M | 77.43M | 23.64M | 3.15M | 0.00 | Gross Profit |
116.76M | 68.13M | 21.50M | 2.56M | -690.00K | EBIT |
-265.50M | -184.36M | -179.16M | -170.06M | -136.57M | EBITDA |
-238.09M | -168.46M | -174.51M | -68.45M | -135.88M | Net Income Common Stockholders |
-260.60M | -184.68M | -183.08M | -68.01M | -130.73M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
320.56M | 275.85M | 333.29M | 294.86M | 172.79M | Total Assets |
392.27M | 332.75M | 382.48M | 329.52M | 187.07M | Total Debt |
3.94M | 1.26M | 1.94M | 2.55M | 3.09M | Net Debt |
-85.20M | -58.82M | -125.73M | -56.70M | -97.77M | Total Liabilities |
227.72M | 162.99M | 118.22M | 45.37M | 20.55M | Stockholders Equity |
21.73M | 169.76M | 264.26M | 284.15M | 166.53M |
Cash Flow | Free Cash Flow | |||
-113.88M | -136.20M | -177.71M | -151.44M | -122.19M | Operating Cash Flow |
-113.88M | -136.16M | -173.43M | -146.00M | -121.98M | Investing Cash Flow |
-48.17M | -5.67M | 28.03M | -62.16M | 158.53M | Financing Cash Flow |
191.24M | 74.37M | 213.83M | 166.48M | 2.01M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
60 Neutral | $3.36B | ― | -39.22% | ― | ― | -31.37% | |
56 Neutral | $2.72B | 10.55 | 54.39% | ― | 624.05% | ― | |
54 Neutral | $3.76B | ― | -272.15% | ― | 68.06% | -35.93% | |
54 Neutral | $3.46B | ― | -46.62% | ― | 3417.33% | 30.06% | |
51 Neutral | $5.35B | 3.41 | -40.83% | 2.89% | 18.11% | 2.60% | |
50 Neutral | $3.27B | ― | -19.20% | ― | -89.95% | -123.71% | |
46 Neutral | $3.75B | ― | -33.47% | ― | 13.99% | 0.17% |
On April 7, 2025, Rhythm Pharmaceuticals announced positive topline results from its Phase 3 TRANSCEND clinical trial evaluating setmelanotide for acquired hypothalamic obesity. The trial met its primary endpoint, showing a significant reduction in BMI in both adult and pediatric patients compared to placebo. These results are seen as a potential milestone for the company, with plans to submit regulatory applications in the U.S. and EU by the third quarter of 2025. The trial’s success could position setmelanotide as the first approved therapy for this condition, impacting the company’s market and stakeholders positively.
Spark’s Take on RYTM Stock
According to Spark, TipRanks’ AI Analyst, (RYTM) is a Neutral.
Rhythm Pharmaceuticals demonstrates strong revenue growth and strategic pipeline advancements, which are significant positives. However, ongoing financial challenges, such as persistent losses and negative cash flow, weigh heavily on the overall assessment. The stock’s technical indicators present mixed signals, while valuation remains difficult due to lack of profitability. Recent corporate moves and the positive sentiment from the earnings call offer some optimism but are offset by high operating expenses and market uptake uncertainties.
To see Spark’s full report on (RYTM) stock, click here.
On March 14, 2025, Rhythm Pharmaceuticals announced the termination of its licensing and share purchase agreements with RareStone Group Ltd., reacquiring the rights to IMCIVREE® (setmelanotide) in China, Hong Kong, and Macau. This strategic move allows Rhythm to own the global franchise for setmelanotide, aligning with its strategy to develop and commercialize treatments for rare neuroendocrine diseases worldwide. The termination agreement includes a repayment of $6.3 million to RareStone and the return of acquired shares without additional consideration, releasing all parties from any claims related to the previous agreements.